Moxifloxacin

證據等級: L5

預測適應症: 10 個

Moxifloxacin: From Bacterial Infections to Bubonic Plague (Yersinia pestis)

One-Sentence Summary

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic; this evidence pack does not include Taiwan/US market or original-indication label data (drug not marketed, MOA field flagged as Data Gap). The TxGNN model generated 10 candidate indications for this drug, but 9 of them (including the top-ranked “polyclonal hyperviscosity syndrome”) have no clinical trial or literature support and are flagged by the evidence pack itself as likely knowledge-graph noise. The only candidate with real pharmacological support is Bubonic Plague, backed by 6 preclinical/PK-PD publications but zero clinical trials.

Note on candidate selection: Per the standard template, the headline indication would default to the TxGNN top rank (polyclonal hyperviscosity syndrome, score 99.98%). That candidate has no clinical trials, no literature, and an explicit rationale note calling it probable “knowledge-graph neighbor noise.” This report instead centers on Bubonic Plague (rank 10), the only candidate with genuine mechanistic and preclinical evidence, so the evaluation is not built on an unsupported signal.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (no Taiwan license data; drug not marketed locally)
Predicted New Indication	Bubonic Plague (Yersinia pestis infection)
TxGNN Prediction Score	99.41%
Evidence Level	L3 (in vitro/in vivo preclinical pharmacodynamic studies)
Market Status (Taiwan)	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed original mechanism-of-action documentation is not available (original_moa: Data Gap), and no Taiwan license/indication data exists because the drug is not marketed locally. However, moxifloxacin’s pharmacological class is well established: it is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and causing bacterial cell death.

For Bubonic Plague specifically, this is not a speculative mechanistic leap. In vitro and in vivo pharmacodynamic studies in the evidence pack confirm moxifloxacin has potent bactericidal activity against Yersinia pestis, the causative agent of plague, via the same DNA gyrase/topoisomerase IV inhibition it uses against other susceptible organisms. Mouse models of systemic and pneumonic plague and dedicated in vitro PK/PD dosing-optimization studies both support this activity, and fluoroquinolones as a class (ciprofloxacin, levofloxacin, moxifloxacin) are already recognized options against Y. pestis.

By contrast, the other nine candidates surfaced by TxGNN for this drug (polyclonal hyperviscosity syndrome, hyperamylasemia, congenital analbuminemia, blood group incompatibility, premalignant hematological disease, monoclonal gammopathy, acquired peripheral neuropathy-associated hematological disease, congenital hematological disorder, hematopoietic/lymphoid neoplasm) all carry near-identical TxGNN scores (>99.9%) but no plausible mechanistic link and, for most, zero supporting evidence. Where clinical trials or literature did surface for the hematology-adjacent candidates, they reflect moxifloxacin being used to treat infections in patients who happen to have those blood diseases (e.g., neutropenic fever, disseminated nocardiosis) — not treatment of the hematological disease itself. This is consistent with the evidence pack’s own assessment that these are likely graph-proximity noise rather than genuine repurposing signals.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21115791	2011	In vitro PK/PD model	Antimicrobial Agents and Chemotherapy	Derived a moxifloxacin dosing regimen that optimizes killing of Y. pestis and prevents emergence of resistance
21486959	2011	In vitro PK/PD model	Antimicrobial Agents and Chemotherapy	Compared moxifloxacin against other candidate antibiotics for Y. pestis in an in vitro pharmacodynamic model
20052916	2009	In vivo/experimental animal	Antibiotiki i khimioterapiia	Moxifloxacin and other fluoroquinolones showed high efficacy (ED50 5.5–14.0 mg/kg) against FI+/FI- Y. pestis strains in mice
15555886	2004	In vivo/experimental animal	International Journal of Antimicrobial Agents	Moxifloxacin offered full protection in a mouse model of systemic and pneumonic plague, comparable to ciprofloxacin
29623187	2018	Case report (adverse event)	Therapeutic Advances in Drug Safety	Case of moxifloxacin-induced tinnitus; notes FDA-recommended use of fluoroquinolones for plague among other indications
26210091	2015	Case report	Ticks and Tick-borne Diseases	Case of Francisella tularensis (tularemia, not plague) infection in China — tangential relevance only

Safety Considerations

Please refer to the package insert for safety information.

(Note: the evidence pack flags this as a blocking data gap — TFDA warnings/contraindications and DDI data were not retrievable, which prevents a formal S1 safety evaluation.)

Conclusion and Next Steps

Decision: Hold

Rationale: Bubonic Plague is supported by credible, mechanistically consistent preclinical evidence (in vitro PK/PD and animal models), but there are no human clinical trials, no market presence for this drug in the target region, and a blocking safety data gap (no TFDA/label warnings, contraindications, or DDI data available). The other nine TxGNN-predicted indications lack any credible mechanistic rationale or supporting evidence and should be deprioritized.

To proceed, the following is needed:

Resolve blocking Data Gap DG001: obtain TFDA/official package insert (warnings, contraindications) before any S1 safety review
Resolve High-severity Data Gap DG002: confirm formal MOA and original approved indications from DrugBank/label source
If pursuing the plague indication: identify a regulatory pathway appropriate for a rare/biodefense indication (human efficacy data is inherently limited for this disease) and evaluate compassionate-use/expanded-access precedent
Deprioritize or formally close out the remaining nine candidate indications given the absence of mechanistic plausibility or evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.